Advertisement

Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes

  • Mira Rosenblat
    Affiliations
    The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, 31096 Haifa, Israel
    Search for articles by this author
  • Rachel Karry
    Affiliations
    The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, 31096 Haifa, Israel
    Search for articles by this author
  • Michael Aviram
    Correspondence
    Corresponding author. Tel.: +972 4 8542970; fax: +972 4 8542130.
    Affiliations
    The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, 31096 Haifa, Israel
    Search for articles by this author

      Abstract

      The present study analyzed serum paraoxonase 1 (PON1) distribution among HDL and lipoprotein-deficient serum (LPDS) in atherosclerotic patients, and compared PON1 biological functions in these fractions.
      Serum HDL and LPDS fractions were isolated from control healthy subjects, diabetic and hypercholesterolemic patients. PON1 activities and protein in HDL/LPDS, as well as its ability to protect against lipid peroxidation and to stimulate HDL/LPDS-mediated macrophage cholesterol efflux were measured. In LPDS from controls, PON1 protein and a significant paraoxonase activity were found, whereas arylesterase and lactonase activities were substantially reduced compared to HDL, by 78% and 88%, respectively. In diabetic patients, PON1 protein and paraoxonase activity in HDL were significantly decreased by 2.8- and 1.7-fold, respectively, compared with controls’ HDL. In parallel, in these patient's LPDS, PON1 protein and paraoxonase activity were markedly increased by 3.7- and 1.7-fold, respectively, compared with controls’ LPDS. PON1 in HDL (but not PON1 in LPDS) significantly decreased AAPH-induced lipid peroxides formation by 33%, and increased macrophage cholesterol efflux by 31%.
      We conclude that PON1 is less antiatherogenic when present in LPDS than in HDL. The abnormal serum PON1 distribution in diabetic patients, could be responsible for the accelerated atherosclerosis development in these patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sorenson R.C.
        • Bisgaier C.L.
        • Aviram M.
        • et al.
        Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity.
        Arterioscler Thromb Vasc Biol. 1999; 19: 2214-2225
        • James R.W.
        • Deakin S.P.
        The importance of high-density lipoprotein for paraoxonase-1 secretion, stability, and activity.
        Free Radic Biol Med. 2004; 37: 1986-1994
        • Teiber J.F.
        • Draganov D.I.
        • La Du B.N.
        Lactonase and lactonizing activities of human serum paraoxonase 1 (PON1) and rabbit serum PON3.
        Biochem Pharmacol. 2003; 66: 887-896
        • Getz G.S.
        • Reardon C.A.
        Paraoxonase, a cardioprotective enzyme: continuing issues.
        Curr Opin Lipidol. 2004; 15: 261-267
        • Mackness M.
        • Durrington P.N.
        • Mackness B.
        Paraoxonase 1 activity, concentration and genotype in cardiovascular diseases.
        Curr Opin Lipidol. 2004; 15: 399-404
        • Fuhrman B.
        • Volkova N.
        • Aviram M.
        Paraoxonase 1 (PON1) is present in postprandial chylomicrons.
        Atherosclerosis. 2005; 180: 55-61
        • Deakin S.
        • Moren X.
        • James R.W.
        Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells.
        Atherosclerosis. 2005; 179: 17-25
        • Harel M.
        • Aharoni A.
        • Gaidukov L.
        • et al.
        Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes.
        Nat Struc Mol Biol. 2004; 11: 412-419
        • Shih D.M.
        • Xia Y.R.
        • Miller E.
        • et al.
        Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis.
        J Biol Chem. 2000; 275: 17527-17535
        • Rozenberg O.
        • Rosenblat M.
        • Coelman R.
        • et al.
        Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice.
        Free Radic Biol Med. 2003; 34: 774-784
        • Tward A.
        • Xia Y.R.
        • Wang X.P.
        • et al.
        Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice.
        Circulation. 2002; 106: 484-490
        • Rozenberg O.
        • Shih S.D.
        • Aviram M.
        Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice.
        Atherosclerosis. 2005; 181: 9-18
        • Aviram M.
        • Rosenblat M.
        • Bisgaier C.L.
        • et al.
        Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase.
        J Clin Invest. 1998; 101: 1581-1590
        • Mackness M.I.
        • Arrol S.
        • Abbott C.A.
        • Durrington P.N.
        Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.
        Atherosclerosis. 1993; 104: 129-135
        • Aviram M.
        • Rosenblat M.
        Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development.
        Free Radic Biol Med. 2004; 37: 1304-1316
        • Fuhrman B.
        • Volkova N.
        • Aviram M.
        Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized LDL in macrophages from atherosclerotic mice: protective role of antioxidants and of paraoxonase.
        Atherosclerosis. 2002; 161: 307-316
        • Rozenberg O.
        • Shih D.M.
        • Aviram M.
        Human serum paraoxonase (PON1) decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase-A2 activity and lysophosphatidylcholine formation.
        Arterioscler Thromb Vasc Biol. 2003; 23: 461-467
        • Rosenblat M.
        • Vaya J.
        • Shih D.M.
        • Aviram M.
        Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine.
        Atherosclerosis. 2005; 179: 69-77
      1. Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004:50:1–7.

        • James R.W.
        • Blatter Garin M.C.
        • Calabresi L.
        • et al.
        Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states.
        Atherosclerosis. 1998; 139: 77-82
        • Noto H.
        • Hashimoto Y.
        • Satoh H.
        • et al.
        Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency.
        Biochem Biophys Res Commun. 2001; 289: 395-401
        • Cabana V.G.
        • Reardon C.A.
        • Feng N.
        • et al.
        Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response.
        J Lipid Res. 2003; 44: 780-792
        • Aviram M.
        Plasma lipoprotein separation by discontinuous density gradient ultracentrifugation in hyperlipoproteinemic patients.
        Biochem Med. 1983; 30: 111-118
        • Connelly P.W.
        • Maguire G.F.
        • Draganov D.I.
        Separation and quantitative recovery of mouse serum arylesterase and carboxyesterase activity.
        J Lipid Res. 2004; 45: 561-566
        • Lowry O.H.
        • Rosenberg N.J.
        • Farr L.
        • Randall R.J.
        Protein measurement with the Folin phenol reagent.
        J Biol Chem. 1951; 193: 225-265
        • Gan K.
        • Smolen A.
        • Eckerson H.W.
        • La Du B.N.
        Purification of human serum paraoxonase/arylesterase: evidence for one esterase catalyzing both activities.
        Drug Metab Dispos. 1991; 19: 100-106
        • Aharoni A.
        • Gaidukov L.
        • Toker L.
        • et al.
        Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.
        Proc Natl Acad Sci. 2003; 101: 482-487
        • Frei B.
        • Stocker R.
        • Ames B.N.
        Antioxidant defenses and lipid peroxidation in human blood plasma.
        Proc Natl Acad Sci USA. 1988; 85: 9748-9752
        • El-Saadani M.
        • Esterbauer N.
        • El-sayed M.
        • et al.
        Spectophotometric assay for lipid peroxides in serum lipoproteins using commercially available reagent.
        J Lipid Res. 1989; 30: 627-630
        • Buege J.A.
        • Aust A.D.
        Microsomal lipid peroxidation.
        Methods Enzymol. 1978; 52: 302-310
        • Draganov D.I.
        • Teiber J.F.
        • Speelman A.
        • et al.
        Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities.
        J Lipid Res. 2005; 46: 1239-1274
        • Aviram M.
        • Rosenblat M.
        Paraoxonases (PONs) and cardiovascular diseases: pharmacological and nutritional influences.
        Curr Opin Lipidol. 2005; 16: 393-399
        • Ahmed Z.
        • Ravandi A.
        • Maguire G.F.
        • et al.
        Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON1) during high density lipoprotein oxidation with peroxynitrite donor.
        J Biol Chem. 2001; 276: 24473-24481
        • Aviram M.
        • Hardak E.
        • Vaya J.
        • et al.
        Human serum paraoxonase (PON1), Q and R selectively decrease lipid peroxides in coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities.
        Circulation. 2000; 101: 2510-2517
        • Letellier C.
        • Duron M.R.
        • Jouanolle A.M.
        • et al.
        Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications.
        Diabetes Metab. 2002; 28: 297-304
        • Tsuzura S.
        • Ikeda Y.
        • Suchiro T.
        • et al.
        Correlation of plasma oxidized low-density lipoprotein levels to vascular complications and human serum paraoxonase in patients with type 2 diabetes.
        Metabolism. 2004; 53: 297-302
        • Ferretti G.
        • Bacchetti T.
        • Busni D.
        • et al.
        Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients.
        J Clin Endocrinol Metab. 2004; 89: 2957-2962
        • Rosenblat M.
        • Hayek T.
        • Hussein K.
        • Aviram M.
        Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
        Arterioscler Thromb Vasc Biol. 2004; 24: 175-180
        • Aviram M.
        • Rosenblat M.
        • Billecke S.
        • et al.
        Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants.
        Free Radic Biol Med. 1999; 26: 892-904
        • Ferretti G.
        • Bacchetti T.
        • Marchionni C.
        • et al.
        Effect of glycation of high density lipoproteins on their physiochemical properties and on paraoxonase activity.
        Acta Diabetol. 2001; 38: 163-169